Evotec SE announced today that the Company has expanded its neurodegeneration collaboration with Bristol Myers Squibb with the initiation of discovery and development efforts regarding a new strategy to tackle neurodegenerative diseases including Alzheimer’s through a novel approach to targeted protein degradation. Evotec receives payments totalling US$ 15 m from Bristol Myers Squibb. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-neuroscience-collaboration-with-bristol-myers-squibb-to-include-new-targeted-protein-degradation-approach-6130